GLUE · Monte Rosa Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Versant Venture Capital VI, L.P. 10% Owner | ▼ Sell | Open Market | 1,573,453 Shares held | 10/29/2024 | View profile |
| Markus Warmuth President & CEO | ▼ Sell | Open Market | 585,038 Shares held | 7/16/2026 | View profile |
| Sharon Townson Chief Scientific Officer | ▼ Sell | Open Market | 67,845 Shares held | 7/6/2026 | View profile |
| Jennifer Champoux Chief Operating Officer | ▼ Sell | Open Market | 62,371 Shares held | 7/15/2026 | View profile |
| Filip Janku Chief Medical Officer | ▼ Sell | Open Market | 60,612 Shares held | 6/30/2026 | View profile |
| Philip Nickson Chief Business & Legal Officer | ▼ Sell | Open Market | 55,000 Shares held | 4/9/2026 | View profile |
| Matthew Bowen Principal Accounting Officer | ▼ Sell | Open Market | 25,891 Shares held | 10/5/2026 | View profile |
| Edmund Dunn Principal Accounting Officer | ▼ Sell | Open Market | 22,554 Shares held | 3/4/2026 | View profile |
| Leo Chandra P. | ▲ Buy | Open Market | 10,000 Shares held | 3/24/2025 | View profile |
| Ali Behbahani Director | ▼ Sell | Other | 0 Shares held | 7/1/2026 | View profile |
| Anthony M. Manning | ▼ Sell | Open Market | 0 Shares held | 6/29/2026 | View profile |
Transaction History
| Matthew Bowen | ▼ Sell | Open Market | 13 | $137 | 10/5/2026 |
| Markus Warmuth | ▼ Sell | Open Market | 9,500 | $220K | 7/16/2026 |
| Jennifer Champoux | ▲ Buy | Option Exercise | 4,351 | $17K | 7/15/2026 |
| Jennifer Champoux | ▼ Sell | Open Market | 4,351 | $102K | 7/15/2026 |
| Sharon Townson | ▲ Buy | Option Exercise | 6,000 | $37K | 7/6/2026 |
| Sharon Townson | ▼ Sell | Open Market | 5,600 | $130K | 7/6/2026 |
| Sharon Townson | ▼ Sell | Open Market | 400 | $10K | 7/6/2026 |
| Ali Behbahani | ▼ Sell | Other | 15,000 | $0 | 7/1/2026 |
| Ali Behbahani | ▼ Sell | Other | 1,000,000 | $0 | 7/1/2026 |
| Ali Behbahani | ▼ Sell | Other | 15,000 | $0 | 7/1/2026 |
| Filip Janku | ▲ Buy | Option Exercise | 5,407 | $73K | 6/30/2026 |
| Filip Janku | ▼ Sell | Open Market | 5,407 | $132K | 6/30/2026 |
| Filip Janku | ▲ Buy | Option Exercise | 6,000 | $45K | 6/29/2026 |
| Filip Janku | ▼ Sell | Open Market | 6,000 | $138K | 6/29/2026 |
| Anthony M. Manning | ▲ Buy | Option Exercise | 10,000 | $42K | 6/29/2026 |
| Anthony M. Manning | ▼ Sell | Open Market | 10,000 | $231K | 6/29/2026 |
| Filip Janku | ▲ Buy | Option Exercise | 30,000 | $227K | 6/24/2026 |
| Filip Janku | ▼ Sell | Open Market | 30,000 | $643K | 6/24/2026 |
| Filip Janku | ▲ Buy | Option Exercise | 6,000 | $45K | 6/23/2026 |
| Filip Janku | ▼ Sell | Open Market | 11,845 | $240K | 6/23/2026 |
| Jennifer Champoux | ▲ Buy | Option Exercise | 2,175 | $9K | 6/23/2026 |
| Jennifer Champoux | ▼ Sell | Open Market | 2,175 | $44K | 6/23/2026 |
| Sharon Townson | ▲ Buy | Option Exercise | 3,000 | $18K | 6/23/2026 |
| Sharon Townson | ▼ Sell | Open Market | 3,000 | $60K | 6/23/2026 |
| Jennifer Champoux | ▲ Buy | Option Exercise | 2,176 | $9K | 6/17/2026 |
| Jennifer Champoux | ▼ Sell | Open Market | 2,176 | $41K | 6/17/2026 |
| Sharon Townson | ▲ Buy | Option Exercise | 3,000 | $18K | 6/17/2026 |
| Sharon Townson | ▼ Sell | Open Market | 3,000 | $57K | 6/17/2026 |
| Markus Warmuth | ▼ Sell | Open Market | 4,998 | $97K | 6/1/2026 |
| Markus Warmuth | ▼ Sell | Open Market | 468 | $9K | 6/1/2026 |
| Sharon Townson | ▲ Buy | Option Exercise | 6,000 | $37K | 5/29/2026 |
| Sharon Townson | ▼ Sell | Open Market | 6,000 | $119K | 5/29/2026 |
| Jennifer Champoux | ▲ Buy | Option Exercise | 2,175 | $9K | 5/27/2026 |
| Jennifer Champoux | ▼ Sell | Open Market | 2,175 | $44K | 5/27/2026 |
| Jennifer Champoux | ▲ Buy | Option Exercise | 2,176 | $9K | 5/22/2026 |
| Jennifer Champoux | ▼ Sell | Open Market | 2,176 | $41K | 5/22/2026 |
| Anthony M. Manning | ▲ Buy | Option Exercise | 10,000 | $42K | 5/21/2026 |
| Anthony M. Manning | ▼ Sell | Open Market | 10,000 | $180K | 5/21/2026 |
| Markus Warmuth | ▼ Sell | Open Market | 5,467 | $103K | 5/1/2026 |
| Markus Warmuth | ▼ Sell | Open Market | 8,000 | $141K | 4/14/2026 |
| Philip Nickson | ▼ Sell | Open Market | 5,845 | $103K | 4/9/2026 |
| Matthew Bowen | ▲ Buy | Grant | 4,300 | — | 4/6/2026 |
| Edmund Dunn | ▼ Sell | Open Market | 139 | $2K | 3/4/2026 |
| Markus Warmuth | ▼ Sell | Open Market | 5,466 | $98K | 3/2/2026 |
| Edmund Dunn | ▲ Buy | Option Exercise | 536 | $7K | 3/2/2026 |
| Edmund Dunn | ▼ Sell | Open Market | 536 | $9K | 3/2/2026 |
| Edmund Dunn | ▲ Buy | Option Exercise | 25,164 | $337K | 2/27/2026 |
| Edmund Dunn | ▼ Sell | Open Market | 25,164 | $456K | 2/27/2026 |
| Filip Janku | ▼ Sell | Open Market | 9,189 | $179K | 2/23/2026 |
| Markus Warmuth | ▼ Sell | Open Market | 3,707 | $86K | 1/7/2026 |
| Markus Warmuth | ▼ Sell | Open Market | 1,450 | $35K | 1/7/2026 |
| Markus Warmuth | ▼ Sell | Open Market | 309 | $8K | 1/7/2026 |
| Philip Nickson | ▼ Sell | Open Market | 3,155 | $48K | 1/5/2026 |
| Jennifer Champoux | ▼ Sell | Open Market | 2,629 | $40K | 1/5/2026 |
| Edmund Dunn | ▼ Sell | Open Market | 1,039 | $16K | 1/5/2026 |
| Markus Warmuth | ▼ Sell | Open Market | 10,135 | $154K | 1/5/2026 |
| Filip Janku | ▼ Sell | Open Market | 3,155 | $48K | 1/5/2026 |
| Sharon Townson | ▼ Sell | Open Market | 3,155 | $48K | 1/5/2026 |
| Philip Nickson | ▲ Buy | Grant | 28,000 | — | 1/2/2026 |
| Jennifer Champoux | ▲ Buy | Grant | 35,000 | — | 1/2/2026 |
| Markus Warmuth | ▲ Buy | Grant | 90,000 | — | 1/2/2026 |
| Filip Janku | ▲ Buy | Grant | 31,000 | — | 1/2/2026 |
| Sharon Townson | ▲ Buy | Grant | 35,000 | — | 1/2/2026 |
| Edmund Dunn | ▼ Sell | Open Market | 2,062 | $9K | 6/3/2025 |
| Leo Chandra P. | ▲ Buy | Open Market | 10,000 | $58K | 3/24/2025 |
| Philip Nickson | ▲ Buy | Grant | 36,000 | — | 1/2/2025 |
| Edmund Dunn | ▲ Buy | Grant | 11,850 | — | 1/2/2025 |
| Filip Janku | ▲ Buy | Grant | 36,000 | — | 1/2/2025 |
| Jennifer Champoux | ▲ Buy | Grant | 30,000 | — | 1/2/2025 |
| Markus Warmuth | ▲ Buy | Grant | 128,000 | — | 1/2/2025 |
| Sharon Townson | ▲ Buy | Grant | 36,000 | — | 1/2/2025 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Open Market | 52,305 | $475K | 10/29/2024 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Open Market | 15,600 | $147K | 10/29/2024 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Open Market | 89,990 | $869K | 10/28/2024 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Other | 1,019,867 | $0 | 10/28/2024 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Other | 20,397 | $0 | 10/28/2024 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Other | 20,397 | $0 | 10/28/2024 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Other | 17,595 | $0 | 10/28/2024 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Other | 17,595 | $0 | 10/28/2024 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Other | 366,590 | $0 | 10/28/2024 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Other | 5,499 | $0 | 10/28/2024 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Other | 5,499 | $0 | 10/28/2024 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Other | 5,454 | $0 | 10/28/2024 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Other | 5,454 | $0 | 10/28/2024 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Open Market | 1,132,566 | $7.4M | 9/20/2024 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Open Market | 9,269 | $57K | 9/13/2024 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Open Market | 16,047 | $96K | 9/12/2024 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Open Market | 541,897 | $3.3M | 9/11/2024 |
| Edmund Dunn | ▼ Sell | Open Market | 1,610 | $6K | 7/5/2024 |
| Edmund Dunn | ▼ Sell | Open Market | 1,207 | $5K | 6/3/2024 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Monte Rosa draws analyst attention on pipeline review and routine disclosures
Recent coverage for Monte Rosa Therapeutics has focused on the company's drug pipeline and balance sheet position, alongside standard disclosures. The company reported inducement grants to employees under a Nasdaq listing rule, which is a routine corporate event. Separately, Monte Rosa announced participation in upcoming investor conferences, giving management a venue to update the market on its clinical programs. Together, these items keep the company visible to investors without altering its underlying outlook.
Monte Rosa draws analyst attention on pipeline review and routine disclosures. Recent coverage for Monte Rosa Therapeutics has focused on the company's drug pipeline and balance sheet position, alongside standard disclosures. The company reported inducement grants to employees under a Nasdaq listing rule, which is a routine corporate event. Separately, Monte Rosa announced participation in upcoming investor conferences, giving management a venue to update the market on its clinical programs. Together, these items keep the company visible to investors without altering its underlying outlook.